Publications by authors named "A Kask"
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (CITN-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses.
View Article and Find Full Text PDFArticle Synopsis
- The Cancer Immunotherapy Trials Network 12 study showed that pembrolizumab is safe and effective for treating advanced Kaposi sarcoma (KS) in people with HIV on antiretroviral therapy.
- In a phase I trial involving 32 participants, 62.1% had a positive response to pembrolizumab, with even higher rates (87.5%) for those who hadn't received previous KS treatments.
- The treatment led to significant progression-free survival, with a median of 28.2 months, and immune-mediated adverse events were effectively managed according to established guidelines.
Affective aspects of a stimulus can be processed rapidly and before cognitive attribution, acting much earlier for verbal stimuli than previously considered. Aimed for specific mechanisms, event-related brain potentials (ERPs), expressed in facial expressions or word meaning and evoked by six basic emotions - - relative to emotionally neutral stimuli were analysed in a sample of 116 participants. Brain responses in the occipital and left temporal regions elicited by the sadness in facial expressions or words were indistinguishable from responses evoked by neutral faces or words.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated a T-helper 1 selective vaccine targeting IGFBP-2 in advanced ovarian cancer patients to elicit strong immune responses and minimize regulatory T cell activity.
- In a phase I trial involving 25 patients, the vaccine was well tolerated and yielded high levels of IFNγ secreting T cells in 50% of participants, with significant increases in certain T cell subsets.
- The findings suggest that the IGFBP-2 vaccine effectively promotes desired type I T cell responses while avoiding regulatory T cell generation, indicating its potential for cancer immunotherapy.